EQRx was a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2020 by Alexis Borisy with a mission to develop and deliver innovative, patent-protected medicines at radically lower prices. The company went public in 2021 through a SPAC merger with CM Life Sciences III and built an oncology and immunology pipeline anchored by in-licensed candidates such as aumolertinib and sugemalimab. In 2023 EQRx wound down its drug-development programs and was acquired by Revolution Medicines in an all-stock transaction. It was surfaced in the API Evangelist network as a portfolio-company lead (backed by a16z and GV); it never operated a public developer platform or API, and its web presence is no longer live.
EQRx is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Biotechnology, and Oncology.
aid: eqrx
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/eqrx.png
name: EQRx
description: EQRx was a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2020 by Alexis Borisy with
a mission to develop and deliver innovative, patent-protected medicines at radically lower prices. The company went public
in 2021 through a SPAC merger with CM Life Sciences III and built an oncology and immunology pipeline anchored by in-licensed
candidates such as aumolertinib and sugemalimab. In 2023 EQRx wound down its drug-development programs and was acquired
by Revolution Medicines in an all-stock transaction. It was surfaced in the API Evangelist network as a portfolio-company
lead (backed by a16z and GV); it never operated a public developer platform or API, and its web presence is no longer live.
url: https://raw.githubusercontent.com/api-evangelist/eqrx/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- gv
x-tier: stub
x-tier-reason: portfolio-lead
x-status: defunct
x-status-note: Acquired by Revolution Medicines (2023); drug-development wound down; no live developer surface.
x-headquarters: Cambridge, Massachusetts, United States
x-founded: '2020'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Biotechnology
- Oncology
- Drug Development
- Life Sciences
- Healthcare
common:
- type: DomainSecurity
url: security/eqrx-domain-security.yml
- type: Website
url: https://eqrx.com
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.